摘要
肝内胆管癌(ICC)是一类高侵袭性的恶性肿瘤,分子机制不明确。其治疗术后易复发且化疗不理想,目前尚无可供特异性早期诊断的生物标记物。近年来研究发现特异性的基因突变如KRAS、EGFR、IDH1和IDH2等,基因甲基化和miRNA等表观遗传学改变,IL-6/STAT,酪氨酸激酶受体相关的信号通路异常激活等参与ICC的发病和转移,其中许多关键基因成为分子靶向药物治疗靶点。我们就其病理机制表观基因组学研究进展作一综述,旨在为促进发现新的诊断和治疗ICC的生物标记物,实施联合分子靶向治疗的策略提供思路。
Intrahepatic cholangiocarcinoma(ICC)is an aggressive malignancy with its molecular mechanism poor understood.It is prone to postoperative relapse and the response of chemotherapy on it is always disappointing.There is no available specific biomarkers for its early diagnosis. Recently, researchers have found that some genetic mutations,such as KRAS,EGFR,IDH1 and IDH2,gene methylation,miRNA and other epigenetic changes,abnormal activation of IL-6/STAT,tyrosine kinase receptors related signaling pathways are involved in ICC pathogenesis.Some of the key genes in it are becoming targets for molecular therapy.We are here to make a review on epigenomic research progress of ICC pathological mechanisms with the aim to promoting discovery of new biomarkers for its diagnosis and treatment,and to providing ideals for new strategy of medication in combination with molecular target drugs.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2014年第11期1294-1298,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
中南大学中央高校基本科研业务费专项资金(2014zzts325)
国家自然科学基金(81273595)
国家863计划(2012AA02A518)
关键词
肝内胆管癌
表观基因组
病理机制
分子靶向治疗
intrahepatic cholangiocarcinoma
epigeneomic
pathological mechanism
molecular target therapy
